Ahmed A, Jain PV, Devi MS. Timing of dental surgery in patients receiving bone-modifying agents: Medication related osteonecrosis of jaw (MRONJ) and implant outcomes in a cohort of 5,284 oncology patients within an integrated dental pathway. J Clin Exp Dent. 2026;18(2):e175-82.

doi:10.4317/jced.63634

___

References

1. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132-5139. https://doi.org/10.1200/JCO.2010.29.7101 PMid:21060033

2. Raje N, Terpos E, Willenbacher W, Shimizu K, García-Sanz R, Durie B, et al. Denosumab versus zoledronic acid in bone disease of newly diagnosed multiple myeloma: an international, double-blind, randomized, controlled, phase 3 study. Lancet Oncol. 2018;19(3):370-381. https://doi.org/10.1016/S1470-2045(18)30072-X PMid:29429912

3. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons' position paper on medication-related osteonecrosis of the jaws-2022 update. J Oral Maxillofac Surg. 2022;80(5):920-943. https://doi.org/10.1016/j.joms.2022.02.008 PMid:35300956

4. Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, et al. Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline. J Clin Oncol. 2019;37(25):2270-2290. https://doi.org/10.1200/JCO.19.01186 PMid:31329513

5. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115-1117. https://doi.org/10.1016/S0278-2391(03)00720-1 PMid:12966493

6. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(10):1479-1491. https://doi.org/10.1359/jbmr.0707onj PMid:17663640

7. Khan AA, Sandor GK, Dore E, Morrison AD, Alsahli M, Amin F, et al. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol. 2008;35(7):1391-1397.

8. De Cicco D, Boschetti CE, Santagata M, Colella G, Staglianò S, Gaggl A, et al. Medication-related osteonecrosis of the jaws: a comparison of SICMF-SIPMO and AAOMS guidelines. Diagnostics (Basel). 2023;13(13):2137. https://doi.org/10.3390/diagnostics13132137 PMid:37443531 PMCid:PMC10340476

9. AlDhalaan NA, BaQais A, Al-Omar A. Medication-related osteonecrosis of the jaw: a review. Int J Health Sci (Qassim). 2020;14(6):18-27. https://doi.org/10.7759/cureus.6944 PMid:32190495 PMCid:PMC7067354

10. Kim JW, Kim SJ. Medication related osteonecrosis of the jaw. J Korean Assoc Oral Maxillofac Surg. 2020;46(3):169-179.

11. Sim IW, Borromeo GL, Tsao C, Hardiman R, Hofman MS, Papatziamos Hjelle C, et al. Declining incidence of medication-related osteonecrosis of the jaw in patients with cancer. J Clin Endocrinol Metab. 2015;100(10):3887-3893. https://doi.org/10.1210/jc.2015-1794 PMid:26241323

12. Schwech N, Tsourdi E, Grsic K, Lippuner K, Zillikens MC, Roldán JC, et al. Incidence and risk factors for medication-related osteonecrosis of the jaw after tooth extractions in cancer patients-A systematic review. Oral Dis. 2023;29(7):2269-2283.

13. Hallmer F, Bjarnadottir O, Götrick B, Malmström P, Andersson G. Incidence of and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis: a population-based study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2020;130(3):252-259. https://doi.org/10.1016/j.oooo.2020.04.808 PMid:32536575

14. Bracchi P, Zecca E, Brunelli C, Bagnasco M, Artioli F, De Vita L, et al. A real-world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with denosumab. Cancer Med. 2023;12(17):18317-18326. https://doi.org/10.1002/cam4.6429 PMid:37559413 PMCid:PMC10523953

15. Kajizono M, Sada H, Ueda N, Ogata T, Hiratsuka A, Shimono T, et al. Incidence and risk factors of osteonecrosis of the jaw in advanced cancer patients after treatment with zoledronic acid or denosumab: a retrospective cohort study. Biol Pharm Bull. 2015;38(12):1850-1855. https://doi.org/10.1248/bpb.b15-00385 PMid:26632176

16. Sacco R, Krowicki M, Braga F, Sprio AE, Greco A, Cappare P. Eighteen years of medication-related osteonecrosis of the jaw: a retrospective analysis of surgical outcomes. Appl Sci (Basel). 2021;11(19):8818. https://doi.org/10.3390/app11198818

17. Thomas JG, Le B, Pirgousis P. Medication-related osteonecrosis of the jaw: a narrative review of pathophysiology, prevention and management. Front Oral Maxillofac Med. 2023;5:28. https://doi.org/10.21037/fomm-21-106

18. Adamska P, Chomik P, Kluza E, Topolnicka K, Jurczyszyn A, Kaczmarzyk T. Treatment of medication-related osteonecrosis of the jaw with platelet-rich fibrin: a retrospective cohort study. J Stomatol (Czestochowa). 2025;75(2):xx-xx. (You may replace this with another firmly indexed MRONJ-treatment paper if preferred.)

19. Jeon HL, Lee H, Oh IS, Yang H, Park J, Shin JY. Zoledronic acid and skeletal-related events in patients with bone metastases and multiple myeloma. Support Care Cancer. 2020;28(2):715-723.

20. Baek YH, Jeon HL, Oh IS, Yang H, Park J, Shin JY. Incidence of skeletal-related events in patients with breast or prostate cancer-induced bone metastasis or multiple myeloma: a 12-year longitudinal nationwide healthcare database study. Cancer Epidemiol. 2019;61:104-110. https://doi.org/10.1016/j.canep.2019.05.013 PMid:31176960

21. Mitchell AP, Winn AN, Dusetzina SB, Shankaran V, et al. Real-world use of bone-modifying agents in metastatic solid tumours. J Natl Cancer Inst. 2022;114(6):840-849.

22. Byrne H, Lang BM, Christopoulos P, Gomez-Roman G, Al-Nawas B, Kammerer P. How we manage medication-related osteonecrosis of the jaw. Eur J Med Res. 2024;29(1):125. https://doi.org/10.1186/s40001-024-01912-6 PMid:39095845 PMCid:PMC11297747